BioMarin Pharmaceutical traded at $58.44 this Thursday October 1st, decreasing $1.56 or 2.60 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 12.74 percent. Over the last 12 months, its price rose by 5.16 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 58.96 by the end of this quarter and at 55.22 in one year, according to Trading Economics global macro models projections and analysts expectations.
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.